Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Sees Large Drop in Short Interest

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) was the recipient of a significant drop in short interest in the month of December. As of December 15th, there was short interest totaling 45,540 shares, a drop of 63.2% from the November 30th total of 123,591 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily volume of 218,008 shares, the days-to-cover ratio is presently 0.2 days. Based on an average daily volume of 218,008 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.0% of the shares of the company are sold short.

Shionogi & Co., Ltd. Unsponsored ADR Price Performance

Shares of OTCMKTS:SGIOY traded up $0.17 during midday trading on Friday, reaching $9.05. 58,010 shares of the company’s stock were exchanged, compared to its average volume of 95,303. The firm has a market capitalization of $15.40 billion, a PE ratio of 14.14, a price-to-earnings-growth ratio of 2.10 and a beta of 0.20. The company’s 50 day simple moving average is $8.51 and its two-hundred day simple moving average is $8.59. Shionogi & Co., Ltd. Unsponsored ADR has a 12 month low of $6.71 and a 12 month high of $9.23. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.74 and a current ratio of 6.44.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last released its quarterly earnings data on Monday, October 27th. The company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.16 by $0.02. The firm had revenue of $740.85 million during the quarter, compared to analyst estimates of $742.35 million. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 11.90% and a net margin of 39.53%. Equities research analysts expect that Shionogi & Co., Ltd. Unsponsored ADR will post 0.66 earnings per share for the current fiscal year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.